Predictors of hospital mortality among patients with COVID-19 in Tehran, Iran

Fatemeh Esfahanian1, SeyedAhmad SeyedAlinaghi2, Nazanin Janfaza3 and Marcarious M. Tantuoyir4

Abstract
Objective: The coronavirus disease 2019 (COVID-19) has become a global pandemic. Timely and effective predictors of survival and death rates are crucial for improving the management of COVID-19 patients. In this study, we evaluated the predictors of mortality based on the demographics, comorbidities, clinical characteristics, laboratory findings, and vital signs of 500 patients with COVID-19 admitted at Imam Khomeini Hospital Complex, the biggest hospital in Tehran, Iran.

Methods: Five hundred hospitalized laboratory-confirmed COVID-19 patients were included in this study. Subsequently, electronic medical records, including patient demographics, clinical manifestation, comorbidities, and laboratory test results were collected and analyzed. They were divided into two groups: expired and discharged. Demographics, clinical, and laboratory data were compared among the two groups. The related factors with death in the patients were determined using univariate and multivariate logistic regression approaches.

Results: Among the 500 hospitalized patients, most patients were male (66.4% versus 33.6%). The expired group had more patients ≥70 years of age compared with the discharged group (32.9% versus 16.3%, respectively). Almost 66% of the expired patients were hospitalized for ≥5 days which was higher than the discharge group (26.9%). Patients with a history of opium use in the expired group were significantly higher compared to the discharged group (14.8% versus 8.6%, p = 0.04) as well as a history of cancer (15.5% versus 4.7%, p < 0.001). Out of the 500 patients with COVID-19, four patients (2.6%) were HIV positive, all of whom expired. Dyspnea (76.4%), fever (56.6%), myalgia (59.9%), and dry cough (67%) were the most common chief complaints of hospitalized patients. Age ≥70 years (adjusted odds ratio = 2.49; 95% confidence interval, 1.02–6.04), being female (adjusted odds ratio = 2.06; 95% confidence interval, 1.25–3.41), days of hospitalization (adjusted odds ratio = 5.73; 95% confidence interval, 3.49–9.41), and having cancer (adjusted odds ratio = 3.23; 95% confidence interval, 1.42–7.39) were identified as independent predictors of mortality among COVID-19 patients.

Conclusion: Discharged and expired COVID-19 patients had distinct clinical and laboratory characteristics, which were separated by principal component analysis. The mortality risk factors for severe patients identified in this study using a multivariate logistic regression model included elderly age (≥70 years), being female, days of hospitalization, and having cancer.

Keywords
COVID-19, Iran, mortality, hospital, predictors

Introduction
In late December 2019, an outbreak of an emerging disease with remarkably high virulence in Wuhan, China, soon became a global concern. The COVID-19 pathogen was discovered to be a novel beta-coronavirus termed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A spectrum of presentations has been reported, ranging from asymptomatic infection to severe lower respiratory tract illness presenting with fever, cough, and dyspnea that may progress to acute respiratory distress syndrome (ARDS) and

1Department of Endocrinology, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
3Internal Medicine Department, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Corresponding author:
Nazanin Janfaza, Internal Medicine Department, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, 1419733141, Iran.
Email: n.janfaza@gmail.com
death. Severe viral pneumonia with respiratory failure and the deterioration of underlying diseases are the main cause of death in severe patients.\textsuperscript{3,4}

Antibodies can be detected quickly and easily in COVID-19 patients. In our quest to understand the path of disease progression in COVID-19 patients, using the serological technique for detecting SARS-CoV-2 in addition to RNA testing is critical. It is suggested that this procedure be used in conjunction with Real-time polymerase chain reaction (RT-PCR) or an RNA test to increase the sensitivity and accuracy of the results. COVID-19 patients can receive prompt diagnosis and management as a result of this technique.\textsuperscript{5} Infection, viral entrance, immunological response to the virus, COVID-19 intensity, and death may all be affected by different genetic patterns. Some genes connected with the immune system’s response have been linked to the severity and predisposition of COVID-19.\textsuperscript{6}

Early reports from Asia and Europe have identified older age, male gender, and chronic medical conditions, such as diabetes mellitus (DM), hypertension, obesity, coronary artery disease (CAD), and heart failure, as associated factors with worse outcomes.\textsuperscript{7} A major problem of the SARS-CoV-2 pandemic is the considerable burden imposed on the National Health System (NHS) worldwide due to the hyper-acute outbreak and the proportional increase of patients requiring intensive care unit (ICU) support in an extremely limited period. As a result, outcomes may differ depending on the disease load in each country.\textsuperscript{8}

Early identification of related factors for critical conditions is crucial, not only to more precisely define the distinguishing clinical and epidemiological characteristics but also to provide adequate supportive care and, if necessary, timely admission to the ICU.\textsuperscript{9} Therefore, this study was aimed to investigate the predictors of hospital mortality based on the demographics, comorbidities, clinical characteristics, laboratory findings, and vital signs of 500 patients with COVID-19 admitted to Imam Khomeini Hospital Complex, the biggest hospital in Tehran, Iran.

Materials and methods

Study design and patient population

The retrospective cross-sectional study was performed on 500 patients with COVID-19 who were admitted to Imam Khomeini Hospital Complex, a referral center in Tehran, Iran, from 20 February to 19 April 2020. All the patients enrolled in the study were admitted after being matched with World Health Organization (WHO) confirmation guidelines of COVID-19 (WHO 2020a). The diagnosis was confirmed by RNA detection of the SARS-CoV-2 in an onsite clinical laboratory. In cases in which polymerase chain reaction (PCR) was not available, lung involvement (all the patients) in favor of COVID-19 was considered as the basis of diagnosis. Out of the total study subjects, 273 (54.6\%) of patients had positive COVID-19 PCR.

Data extraction

All information of this study was obtained using a structured questionnaire from electronic patient health records. The questionnaire was adopted from previous similar studies by Alamdari et al.\textsuperscript{10} and SeyedAlinaghi et al.\textsuperscript{11} and it was modified and used only by the authors purposely for carrying out this study (Supplemental Material). Table 1 shows the collected data through the questionnaire.

Ethical considerations

The research protocol was fully assessed and approved by the Ethics Committee, Deputy of Research, Tehran University of Medical Sciences, Tehran, Iran (ethics approval code: 99-1-101-47345).

Sample size calculation

For the sample size calculation and data synthesis, z tests–logistic regression was used with our type I error rate ($\alpha$ err

| Table 1. List of the variables included in the data analysis. |
|-------------------------------------------------------------|
| Demographics                                                   |
| Signs, symptoms, and related morbidities                      |
| Gender                                                       |
| Dyspnea                                                       |
| Age                                                          |
| Fever                                                        |
| Marital status                                                |
| Headache                                                      |
| Duration of admission                                         |
| Sore throat                                                   |
| Comorbidities                                                 |
| Chills                                                       |
| Coronary artery disease (CAD)                                 |
| Fatigue                                                      |
| Hypertension                                                 |
| Myalgia                                                      |
| Diabetes mellitus (DM)                                        |
| Coryza                                                       |
| Chronic pulmonary disease                                    |
| Cough                                                        |
| Chronic liver disease                                        |
| Vomiting                                                     |
| HIV                                                          |
| Nausea                                                       |
| Chronic renal failure (CRF)                                   |
| Hemoptysis                                                   |
| Cancer                                                       |
| Appetite loss                                                |
| Hypothyroid                                                  |
| Chest pain                                                   |
| Hyperthyroid                                                 |
| Dizziness                                                    |
| Smoking history                                              |
| Anosmia                                                      |
| Opium history                                                |

Laboratory findings and vital signs

| O$_2$ saturation     | Body mass index |
|----------------------|-----------------|
| Temperature          | Fasting blood sugar (FBS) |
| Pulse rate           | d-dimer         |
| Respiratory rate     | Lactate dehydrogenase |
| Creatine phosphokinase | Calcium       |
| Potassium            | AST             |
| Sodium               | ALT             |
| Phosphorous          | Erythrocyte sedimentation rate (ESR) |
| C-reactive protein (CRP) | Platelet |
| White blood cell (WBC) | Lymphocyte count |

AST: aspartate transaminase; ALT: alanine transaminase.
Outcomes and statistical analysis

Data extraction and analysis were performed with IBM SPSS Statistics software (version 25). In our calculations, a z test for logistic regression for a continuous predictor helped us to test whether a continuous predictor is a significant predictor of a binary outcome, with or without other covariates. However, for better interpretations, continuous variables were converted to categorical characteristics based on the evidence and experience of the researchers. An univariate analysis looks at each element in a dataset individually and analyzes the response pattern to that variable, whereas the investigation of two variables to identify the empirical relationship between them is known as bivariate analysis (Table 2). On the other hand, multivariate analysis is a statistical process for analyzing data including multiple types of measurements or observations as well as used in circumstances in which more than one dependent variable is investigated at the same time as other variables. Considering the type of dataset obtained for this study, the former two (univariate and bivariate logistic analysis) were not appropriate; hence, multivariate analysis was used in investigating the predictors of mortality within the hospital. As such, a value of p ≤ 0.10 was considered statistically significant for our multivariate logistic analysis.11 We further adjusted all the variables utilized in our analysis because we had numerous independent variables and also to control other predictor variables and account for the dynamics between the predictors in our multivariate regression analysis. Table 2 gives the variables used in our final analysis with their respective adjusted odds ratios (AORs). In the final model, factors associated with hospital mortality were considered based on reports and evidence from previous studies at the p < 0.05 level (Alamdari et al.10 and SeyedAlinaghi et al.11 presented the p < 0.10 level for potential predictors and the p < 0.05 level for final predictors of characteristics associated with COVID-19 mortality).

Results

Descriptive characteristics

The demographic and clinical characteristics of the patients are described in Table 2. Briefly, among 500 hospitalized patients, most patients were male (66.4% versus 33.6%). The expired group had more patients ≥ 70 years of age compared with the discharged group (32.9% versus 16.3%, respectively). We compared men and women in different age groups. There was no significant difference between them (p = 0.83). A total of 66.2% of expired patients were hospitalized for ≥ 5 days which was higher than the discharge group (26.9%). Respectively, 19.4% and 16.0% of discharged and expired groups had a history of smoking which showed no statistically significant difference (p = 0.36); however, patients with a history of opium use in the expired group was significantly higher compared to the discharged group (14.8% versus 8.6%, p = 0.04) as well as a history of cancer (15.5% versus 4.7%, p < 0.001). Finally, out of 500 patients with COVID-19, four patients (2.6%) were HIV positive, all of whom expired. One hundred fifty-two (30.4%) of patients did not have the COVID-19 PCR test available. But, all the patients had lung involvement in favor of COVID-19.

Associated factors

Table 2 indicates that dyspnea (76.4%), fever (56.6%), myalgia (59.9%), and dry cough (67%) were the most common chief complaints of hospitalized patients, whereas hemoptysis (0.8%), coryza (0.6%), and dizziness (0.8%) were the least common ones. In addition, dyspnea has been reported considerably more in the expired group rather than the discharged one (p = 0.09).

Almost 84% of patients had less than 93% oxygen saturation when they entered the hospital. The following laboratory findings were significantly more common in patients with the final status of death: (1) increased alanine transaminase (ALT) (p = 0.07) and aspartate transaminase (AST) (p = 0.03), (2) decreased lymphocyte count (p < 0.001), and (3) increased levels of lactate dehydrogenase (LDH) (p = 0.004).

Thereupon, all the variables associated with hospital mortality of COVID-19 at the p ≤ 0.10 level were entered into a multivariate regression model, and the results are summarized in Table 3. Age ≥ 70 years (AOR = 2.49; 95% confidence interval (CI), 1.25–4.91), being female (AOR = 2.06; 95% CI, 1.25–3.41), the number of days of hospitalization (AOR = 5.73; 95% CI, 3.49–9.41), and having cancer (AOR = 3.23; 95% CI, 1.42–7.39) were identified as independent predictors of mortality among COVID-19 patients.

Discussion

Patients’ characteristics

The percentage of older age (≥ 70 years) in patients who died was much higher than those who survived. This study supports the association of elderly age with an increased mortality rate in COVID-19 patients which is consistent with a previous study.9 Older age has already been previously identified as a significant, independent mortality predictor in the Middle East respiratory syndrome (MERS) and SARS. Age-related impairments in T-cell and B-cell activity, as well as an excess of type 2 cytokines, may result in a lack of viral replication control and longer pro-inflammatory responses, potentially resulting in poor prognosis.12–15

Interestingly, our findings are somewhat different from the global picture in regard to male versus female mortality. It is widely known that gender is also a risk factor for higher
Table 2. Demographic, clinical, and laboratory findings of patients with COVID-19 based on two groups, Imam Khomeini Hospital Complex, Tehran, 2020.

| Variables                        | Groups          | OR (95% CI) | P-value |
|----------------------------------|-----------------|-------------|---------|
|                                  | Expire N (%)    | Discharge N (%) |         |         |
| Total                            | 155 (31.4%)     | 338 (68.6%)  |         |         |
| Gender                           |                 |             |         |         |
| Male                             | 89 (57.4%)      | 243 (71.9%)  | 0.52 (0.35–0.78) | 0.002 |
| Female                           | 66 (42.6%)      | 95 (28.1%)   |         |         |
| Age (years)                      |                 |             |         |         |
| <39                              | 17 (11.0%)      | 50 (14.8%)   | 0.52 (0.29–0.94) | 0.51  |
| 39–49                            | 16 (10.3%)      | 61 (18.0%)   | 0.56 (0.35–0.91) | 0.67  |
| 50–59                            | 27 (17.4%)      | 92 (27.2%)   | 1.28 (0.83–1.97) | 0.15  |
| 60–69                            | 44 (28.4%)      | 80 (23.7%)   | 2.52 (1.62–3.93) | 0.003 |
| ≥70                              | 51 (32.9%)      | 55 (16.3%)   |         |         |
| Duration of admission (days)     |                 |             |         |         |
| <5                               | 52 (33.8%)      | 247 (73.1%)  | 5.32 (3.52–8.03) | <0.001|
| ≥5                               | 102 (66.2%)     | 91 (26.9%)   |         |         |
| Marital status                   |                 |             |         |         |
| Single                           | 9 (5.9%)        | 29 (8.7%)    | 1.52 (0.70–3.30) | 0.28  |
| Married                          | 144 (64.1%)     | 304 (91.3%)  |         |         |
| Coronary artery disease (CAD)    |                 |             |         |         |
| Yes                              | 49 (31.6%)      | 84 (24.9%)   | 1.39 (0.91–2.11) | 0.12  |
| Hypertension                     | 65 (41.9%)      | 116 (34.3%)  | 1.38 (0.93–2.04) | 0.10  |
| Diabetes mellitus (DM)           |                 |             |         |         |
| Yes                              | 43 (27.9%)      | 91 (26.9%)   | 1.05 (0.68–1.61) | 0.82  |
| Chronic pulmonary disease        |                 |             |         |         |
| Yes                              | 13 (8.4%)       | 27 (8.0%)    | 1.05 (0.52–2.10) | 0.88  |
| HIV                              |                 |             |         |         |
| Yes                              | 4 (2.6%)        | 0 (0.0%)     | 20.69 (1.11–386.85) | 0.99  |
| Chronic liver disease            |                 |             |         |         |
| Yes                              | 4 (2.6%)        | 8 (2.4%)     | 1.09 (0.32–3.68) | 0.89  |
| Chronic renal failure (CRF)      |                 |             |         |         |
| Yes                              | 11 (7.1%)       | 14 (4.1%)    | 1.76 (0.78–3.98) | 0.17  |
| Cancer                           |                 |             |         |         |
| Yes                              | 24 (15.5%)      | 16 (4.7%)    | 3.68 (1.89–7.16) | <0.001|
| Hypothyroid                      |                 |             |         |         |
| Yes                              | 21 (13.5%)      | 44 (13.0%)   | 1.04 (0.59–1.83) | 0.87  |
| Hyperthyroid                     |                 |             |         |         |
| Yes                              | 2 (1.3%)        | 0 (0.0%)     | 11.19 (0.53–234.55) | 0.99  |
| Smoking history                  |                 |             |         |         |
| Yes                              | 30 (19.4%)      | 54 (16.0%)   | 1.26 (0.77–2.06) | 0.36  |
| Opium history                    |                 |             |         |         |
| Yes                              | 23 (14.8%)      | 29 (8.6%)    | 1.85 (1.03–3.31) | 0.04  |
| Exposure history                 |                 |             |         |         |
| Yes                              | 29 (18.8%)      | 71 (21.1%)   | 0.86 (0.53–1.40) | 0.57  |
| Dyspnea                          |                 |             |         |         |
| Yes                              | 126 (81.3%)     | 251 (74.3%)  | 1.50 (0.94–2.41) | 0.09  |
| Fever                            |                 |             |         |         |
| Yes                              | 94 (60.6%)      | 187 (55.3%)  | 1.24 (0.84–1.83) | 0.27  |
| Headache                         |                 |             |         |         |
| Yes                              | 17 (11.0%)      | 50 (14.8%)   | 0.71 (0.39–1.27) | 0.25  |
| Sore throat                      |                 |             |         |         |
| Yes                              | 3 (1.9%)        | 26 (7.7%)    | 0.23 (0.07–0.79) | 0.02  |

(Continued)
| Variables                      | Groups |                  | OR (95% CI) referent | P-value      |
|-------------------------------|--------|------------------|----------------------|-------------|
|                               |        | Expire N (%)     | Discharge N (%)      |             |
| Chills                        | Yes    | 56 (36.1%)       | 138 (40.8%)          | 0.58 (0.35–0.95) | 0.75        |
| Fatigue                       | Yes    | 15 (9.7%)        | 22 (6.5%)            | 1.53 (0.77–3.05) | 0.22        |
| Myalgia                       | Yes    | 82 (52.9%)       | 211 (62.4%)          | 0.67 (0.46–0.99) | 0.05        |
| Coryza                        | Yes    | 0 (0.0%)         | 3 (0.9%)             | 0.32 (0.01–6.32) | 0.99        |
| Cough                         | Yes    | 109 (70.3%)      | 221 (65.4%)          | 1.25 (0.83–1.89) | 0.28        |
| Vomiting                      | Yes    | 23 (14.8%)       | 58 (17.2%)           | 0.84 (0.49–1.42) | 0.52        |
| Nausea                        | Yes    | 21 (13.5%)       | 68 (20.1%)           | 0.62 (0.36–1.05) | 0.08        |
| Diarrhea                      | Yes    | 13 (8.4%)        | 30 (8.9%)            | 0.94 (0.47–1.85) | 0.86        |
| Hemoptysis                    | Yes    | 1 (6.0%)         | 3 (0.9%)             | 0.72 (0.07–6.98) | 0.65        |
| Appetite loss                 | Yes    | 35 (22.6%)       | 96 (28.4%)           | 0.73 (0.47–1.14) | 0.18        |
| Chest pain                    | Yes    | 15 (9.7%)        | 52 (15.4%)           | 0.58 (0.32–1.08) | 0.09        |
| Dizziness                     | Yes    | 0 (0.0%)         | 4 (1.2%)             | 0.24 (0.01–4.54) | 0.99        |
| Anosmia                       | Yes    | 13 (8.4%)        | 24 (7.1%)            | 1.19 (0.59–2.42) | 0.62        |
| Fasting blood sugar (FBS)     | <126   | 13 (8.4%)        | 9 (2.7%)             | 0.61 (2.85–13.3) | 0.42        |
|                               | ⩾126   | 23 (14.8%)       | 10 (3.0%)            |             |             |
| D-dimer (mg/liter)            | <290   | 1 (0.6%)         | 1 (0.3%)             | 0.95 (0.38–2.37) | 0.86        |
|                               | ⩾290   | 7 (4.5%)         | 16 (4.7%)            |             |             |
| Lactate dehydrogenase         | <480   | 16 (10.3%)       | 41 (12.1%)           | 1.96 (1.30–2.95) | 0.004       |
|                               | ⩾480   | 75 (48.4%)       | 111 (32.8%)          |             |             |
| Creatine phosphokinase        | <195   | 23 (14.8%)       | 43 (12.7%)           | 1.97 (0.96–4.04) | 0.15        |
|                               | ⩾195   | 15 (9.7%)        | 18 (5.3%)            |             |             |
| Potassium                     | <3.5   | 12 (7.7%)        | 17 (5.0%)            | 1.49 (0.91–2.42) | 0.13        |
|                               | 3.5–5.0| 100 (64.5%)      | 211 (62.4%)          | 2.14 (0.98–4.68) | 0.05        |
|                               | ⩾5.1   | 15 (9.7%)        | 22 (6.5%)            |             |             |
| Sodium                        | <135   | 19 (12.3%)       | 37 (10.9%)           | 1.59 (0.98–2.59) | 0.03        |
|                               | 135–145| 101 (65.2%)      | 206 (60.9%)          |             |             |
|                               | ⩾146   | 7 (4.5%)         | 4 (1.2%)             | 5.68 (1.55–20.85) | 0.009       |
| Phosphorus                    | <2.5   | 9 (5.8%)         | 9 (2.7%)             | 1.37 (0.86–2.18) | 0.17        |
|                               | 2.5–5.0| 37 (23.9%)       | 67 (19.8%)           |             |             |
|                               | ⩾5.1   | 6 (3.9%)         | 5 (1.5%)             | 2.99 (0.89–10.02) | 0.07        |
### Table 2. (Continued)

| Variables                              | Groups                                      | OR (95% CI) referent | P-value referent |
|----------------------------------------|---------------------------------------------|-----------------------|------------------|
|                                        | Expire N (%)a                              | Discharge N (%)a      |                  |
| Calcium                                |                                             |                       |                  |
| <8.6                                   | 45 (29.0%)                                 | 42 (12.4%)            | 0.56 (0.27–1.17) | 0.12             |
| 8.6–10.2                               | 10 (6.5%)                                  | 44 (13.0%)            | 0.62 (0.06–5.67) | 0.67             |
| ≥10.3                                  | 1 (6.0%)                                   | 4 (1.2%)              |                  |
| AST                                     |                                             |                       |                  |
| <41                                    | 49 (31.6%)                                 | 129 (38.2%)           | 1.68 (1.04–2.73) | 0.03             |
| ≥41                                    | 47 (30.3%)                                 | 67 (19.8%)            |                  |
| ALT                                     |                                             |                       |                  |
| <41                                    | 58 (37.4%)                                 | 143 (42.3%)           | 1.72 (1.03–2.88) | 0.07             |
| ≥41                                    | 38 (24.5%)                                 | 53 (15.7%)            |                  |
| Erythrocyte sedimentation rate (ESR)   |                                             |                       |                  |
| <16                                    | 5 (3.2%)                                   | 23 (6.8%)             | 1.29 (0.73–2.28) | 0.36             |
| ≥16                                    | 117 (75.5%)                                | 244 (72.2%)           | 1.03 (0.64–1.64) | 0.89             |
| C-reactive protein (CRP) mg/liter      |                                             |                       |                  |
| <6                                     | 1 (0.6%)                                   | 8 (2.4%)              |                  |
| ≥6                                     | 135 (87.1%)                                | 279 (82.5%)           |                  |
| Platelet                               |                                             |                       |                  |
| <150,000                               | 153 (98.7%)                                | 329 (97.3%)           | 1.87 (0.21–16.84)| 0.29             |
| ≥150,000                               | 0 (0.0%)                                   | 3 (0.9%)              |                  |
| White blood cell (WBC)                 |                                             |                       |                  |
| <4000                                  | 24 (15.5%)                                 | 39 (11.5%)            | 0.39 (0.05–2.82) | 0.35             |
| 4000–9999                              | 83 (53.5%)                                 | 212 (62.7%)           | 0.54 (0.07–3.96) | 0.54             |
| ≥10,000                                | 46 (29.7%)                                 | 85 (25.1%)            |                  |
| Lymphocyte count                       |                                             |                       |                  |
| ≤1000                                  | 103 (69.1%)                                | 172 (52.8%)           | 0.49 (0.33–0.75) | 0.001            |
| >1000                                  | 46 (30.9%)                                 | 154 (47.2%)           |                  |
| O₂ saturation                          |                                             |                       |                  |
| <93                                    | 134 (86.5%)                                | 284 (84.0%)           | 1.12 (0.34–3.62) | 0.85             |
| ≥93                                    | 16 (10.3%)                                 | 40 (11.8%)            |                  |
| Temperature (°C)                       |                                             |                       |                  |
| <37.3                                  | 41 (26.5%)                                 | 151 (44.7%)           | 1.07 (0.56–2.03) | 0.83             |
| 37.3–38                                | 66 (42.6%)                                 | 107 (31.7%)           |                  |
| 38.1–39                                | 25 (16.1%)                                 | 31 (9.2%)             | 1.40 (0.64–3.03) | 0.39             |
| ≥39.1                                  | 4 (2.6%)                                   | 16 (4.7%)             | 0.43 (0.12–1.48) | 0.18             |
| Pulse rate                             |                                             |                       |                  |
| <60                                    | 5 (3.2%)                                   | 10 (3.0%)             | 0.68 (0.36–1.25) | 0.21             |
| 60–99                                  | 69 (44.5%)                                 | 208 (61.5%)           | 1.57 (0.82–2.98) | 0.16             |
| ≥100                                   | 62 (40.0%)                                 | 81 (24.0%)            |                  |
| Respiratory rate                       |                                             |                       |                  |
| <25                                    | 57 (36.8%)                                 | 121 (35.8%)           | 2.41 (1.46–4.0)  | 0.001            |
| ≥25                                    | 43 (27.7%)                                 | 53 (15.7%)            |                  |
| Body mass index                        |                                             |                       |                  |
| <30                                    | 1 (0.6%)                                   | 13 (3.8%)             | 1.08 (0.06–19.31)| 0.96             |
| ≥30                                    | 1 (0.6%)                                   | 12 (3.6%)             |                  |
| Drug history                           |                                             |                       |                  |
| Yes                                    | 76 (49.0%)                                 | 150 (44.5%)           | 1.19 (0.81–1.75) | 0.35             |
| No                                     | 79 (51.0%)                                 | 187 (55.5%)           |                  |

OR: odds ratio; CI: confidence interval; AST: aspartate transaminase; ALT: alanine transaminase.

*aSubgroups do not always add up to total due to missing data.
Table 3. Independent associations with the hospital mortality of COVID-19 in multiple conditional logistic regression analysis; Imam Khomeini Hospital, Tehran, 2020.

| Factors                  | AOR     | 95% CI     | P-value |
|--------------------------|---------|------------|---------|
| Gender                   |         |            |         |
| Female                   | 2.06    | 1.25–3.41  | 0.005   |
| Male Referent            | Referent| Referent   | Referent|
| Age (years)              |         |            |         |
| <39 Referent             | Referent| Referent   | Referent|
| 39–49                    | 0.92    | 0.36–2.35  | 0.87    |
| 50–59                    | 0.45    | 0.18–1.13  | 0.09    |
| 60–69                    | 1.38    | 0.58–3.23  | 0.46    |
| ≥70                      | 2.49    | 1.02–6.04  | 0.04    |
| Duration of admission (days) |      |            |         |
| 0–5 Referent             | Referent| Referent   | Referent|
| >5                       | 5.73    | 3.49–9.41  | <0.001  |
| Hypertension             | 1.05    | 0.62–1.78  | 0.10    |
| Opium history            | 0.68    | 0.32–1.45  | 0.04    |
| Dyspnea                  | 0.67    | 0.36–1.22  | 0.09    |
| Cancer                   | 3.23    | 1.42–7.39  | 0.005   |
| Chest pain               | 2.26    | 1.09–4.72  | 0.02    |
| Lactate dehydrogenase    |         |            |         |
| <480 Referent            | Referent| Referent   | Referent|
| ≥480                     | 1.49    | 0.88–2.53  | 0.004   |
| Calcium                  |         |            |         |
| <8.6 Referent            | Referent| Referent   | Referent|
| 8.6–10.2                 | 0.49    | 0.21–1.14  | 0.12    |
| ≥10.3                    | 0.39    | 0.39–3.98  | 0.67    |
| ALT                      |         |            |         |
| <41 Referent             | Referent| Referent   | Referent|
| ≥41                      | 0.90    | 0.39–1.85  | 0.007   |
| Pulse rate               |         |            |         |
| <60 Referent             | Referent| Referent   | Referent|
| 60–99                    | 0.57    | 0.26–1.21  | 0.21    |
| ≥100                     | 1.54    | 0.60–3.37  | 0.16    |
| Respiratory rate         |         |            |         |
| <25 Referent             | Referent| Referent   | Referent|
| ≥25                      | 0.49    | 0.28–0.87  | 0.001   |

AOR: adjusted odds ratio; CI: confidence interval; ALT: alanine transaminase.

severity and COVID-19 mortality, independent of age and susceptibility. However, this study found that although men were more likely to be infected than women, women were at a higher risk of death suggesting a typical regional pattern rather than a global pattern.

We found that most patients who were discharged had less than 5 days of hospitalization and the length of hospitalization was significantly associated with mortality. This also suggests that the duration of hospital greater than 5 days may put a COVID-19 patient at a higher risk of death. Concerning this, a study was conducted in Iran on 500 COVID-19 patients. It reported an average hospital stay of 10 days. Another interesting point of our study showed that patients with a history of opium use were significantly higher in the expired group compared to the discharged group. However, this may need further investigations to ascertain the exact correlation between mortality rate and opium use in COVID-19 patients.

In terms of COVID-19 patients with a smoking history, a meta-analysis of 1399 COVID-19 cases in a Chinese population found that current smoking status is not related to an elevated risk of poor prognoses in COVID-19 patients which is consistent with our findings. This may point toward a negative relation between the history of smoking and mortality in COVID-19 patients.

Comorbidities

Comorbidities such as DM, hypertension, and cancer predispose COVID-19 patients to poor clinical outcomes, similar to other severe acute respiratory outbreaks, according to our findings. In our analysis, cancer was also attributed to a considerable chance of death. Based on our personal experience, vital medical care for cancer patients was not readily available throughout this outbreak. According to a study on the likelihood for deadly COVID-19 in cancer patients, a small number of patients who were readmitted had other identifiable risk factors for severe disease, rather than the malignancy-specific etiology. In other words, due to complex conditions generated by the malignancy and the co-existing states of chemotherapy and/or radiotherapy, individuals with malignancy cannot be examined and properly assessed.

Clinical manifestations

The most common signs and symptoms were dyspnea, fever, cough, and myalgia. Although a recent study has demonstrated that losing the sense of smell and taste in patients with influenza-like illness manifestations is significantly present in SARS-COV-2 infection, we identified anosmia in 7.4% of all patients. The prevalence of anosmia/hyposmia and ageusia/dysgeusia was found to be 10.5% and 7.5%, respectively, among COVID-19 patients in a similar Iranian study, which overall was more common than what we found in our study.

Laboratory findings

In our investigation, an increased level of LDH and declined levels of lymphocytes were revealed to be significant prognostic predictors of the disease. Similarly, high blood pressure, hypoxia, leukocytosis, lymphopenia, and high serum LDH levels have all been found to be independent predictors of in-hospital mortality in various investigations.

Study limitations

This investigation was limited to a small number of cases, which may have hampered statistical power, as well as the
inclusion of only hospitalized patients (non-hospitalized patients were not included in the analysis). Because of these restrictions, differences in demographic and clinical variables, as well as laboratory data, may exist between the groups. In addition, missing data on some variables, such as information of computerized tomography (CT) scans, may cause a lack of the identification of other associated factors for mortality in the patients. Also, the study questionnaire has not been validated since it was designed and used by only the authors, per our experience, in gathering the data.

Conclusion
The mortality risk factors for hospitalized patients found in this study using a multivariate logistic regression model include an elderly age (≥70 years), being a female, the number of days of hospitalization, and having cancer. Even though opium history, lymphocyte counts, and LDH levels were considerably different in expired and discharged patients, these variables were not determined to be independently related factors for COVID-19 patients’ death. However, assessment of these parameters may help to identify severe COVID-19 patients at a higher risk of death. Ultimately, earlier medical intervention and support on these patients with high risk may reduce the fatality of this disease.

Acknowledgements
The authors would like to appreciate the staff of the hospital for their help.

Author contributions
Fatemeh Esfahanian helped in the conception and design of the study. SeyyedAhmad SeyyedAlinaghi helped in the analysis, interpretation of data, and revising. Nazanin Janfaza helped in drafting the article and final approval of the version to be submitted. Marcarious M. Tantuoyir helped in rewriting and editing of text for submission.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
The research protocol was fully assessed and approved by the Ethics Committee, Deputy of Research, Tehran University of Medical Sciences, Tehran, Iran (ethics approval code: 99-1-101-47345)

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Tehran University of Medical Sciences.

Informed consent
We declare that the study was performed according to the international, national, and institutional rules considering animal experiments, clinical studies, and biodiversity rights. Our institution is an educational and research center; hence, before a patient is hospitalized, an explanation is given about the research activities and the consent (oral) to use the patients’ files for research work is obtained. More also, since our work was only to obtain data from patients’ electronic health records, the study was done after patients were either discharged or died, hence no room to obtain written consent.

ORCID iDs
Nazanin Janfaza https://orcid.org/0000-0002-0990-620X
Marcarious M. Tantuoyir https://orcid.org/0000-0002-7645-9999

Supplemental material
Supplemental material for this article is available online.

References
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733.
2. Ghiassvand F, Ghadimi M, Ghadimi F, et al. Symmetrical polyneuropathy in coronavirus disease 2019 (COVID-19). Idcases 2020; 21: e00815.
3. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1967–1976.
4. Svehaveti J, Jafari F, SeyyedAlinaghi S, et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. Int J Antimicrob Agents 2020; 56(4): 106143.
5. Tantuoyir MA-O and Rezaei NA-O. Serological tests for COVID-19: potential opportunities. Cell Biol Int 2021; 45(4): 740–748.
6. SeyyedAlinaghi S, Mehtmakt M, MohssenPour M, et al. Genetic susceptibility of COVID-19: a systematic review of current evidence. Eur J Med Res 2021; 26(1): 46.
7. Mehran E, Karimi A, Barzegary A, et al. Predictors of mortality in patients with COVID-19: a systematic review. Eur J Int Med 2020; 40: 101226.
8. Halvatsiotis P, Kotanidou A, Tsannis K, et al. Demographic and clinical features of critically ill patients with COVID-19 in Greece: the burden of diabetes and obesity. Diabetes Res Clin Pract 2020; 166: 108331.
9. Yuki K, Fujiogi M and Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol 2020; 215: 108427.
10. Alamdari NM, Afaghi S, Rahimi FS, et al. Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku J Exp Med 2020; 252(1): 73–84.
11. SeyyedAlinaghi S, Abbasian L, Solduzian M, et al. Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study. Eur J Med Res 2021; 26(1): 41.
12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513.
13. Zhang Dong X, Cao YY, Yuan YD, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7): 1730–1741.
14. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061–1069.
15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 394: 1054–1062.

16. Jin J-M, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. *Front Public Health* 2020; 8: 152.

17. Lippi G and Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). *Eur J Int Med* 2020; 75: 107–108.

18. Mehraeen E, Behnezhad F, Salehi MA, et al. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. *Eur Archiv Oto-Rhino-Laryngol* 2020; 2020: 1–6.

19. Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. *J Med Virol* 2020; 92(10): 1875–1883.

20. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020; 146(1): 110–118.